Which has higher earnings and valuation, BLLN or PSNL?

Billiontoone has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Billiontoone $354.54M 15.61 $7.45M $0.55 218.82 Personalis $64.52M 22.11 -$81.27M -$1.02 N/A

Does the media refer more to BLLN or PSNL?

In the previous week, Billiontoone had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for Billiontoone and 3 mentions for Personalis. Personalis' average media sentiment score of 0.29 beat Billiontoone's score of 0.04 indicating that Personalis is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Billiontoone 1 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Neutral Personalis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media favor PSNL or CAI?

In the previous week, Caris Life Sciences had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Personalis. Caris Life Sciences' average media sentiment score of 0.50 beat Personalis' score of 0.29 indicating that Caris Life Sciences is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Personalis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Caris Life Sciences 1 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Which has higher valuation and earnings, SHC or PSNL?

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Sotera Health $1.16B 4.39 $77.94M $0.41 43.73 Personalis $64.52M 22.11 -$81.27M -$1.02 N/A

Is SHC or PSNL more profitable?

Sotera Health has a net margin of 9.91% compared to Personalis' net margin of -148.11%. Sotera Health's return on equity of 39.73% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Sotera Health 9.91% 39.73% 7.05% Personalis -148.11% -43.52% -32.92%

Does the media prefer SHC or PSNL?

In the previous week, Personalis had 2 more articles in the media than Sotera Health. MarketBeat recorded 3 mentions for Personalis and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.95 beat Personalis' score of 0.29 indicating that Sotera Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Sotera Health 0 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation & earnings, CELC or PSNL?

Personalis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Celcuity N/A N/A -$177.04M -$3.90 N/A Personalis $64.52M 22.11 -$81.27M -$1.02 N/A

Is CELC or PSNL more profitable?

Celcuity has a net margin of 0.00% compared to Personalis' net margin of -148.11%. Personalis' return on equity of -43.52% beat Celcuity's return on equity. Company Net Margins Return on Equity Return on Assets Celcuity N/A -244.61% -50.22% Personalis -148.11% -43.52% -32.92%

Which has higher valuation and earnings, VCYT or PSNL?

Veracyte has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Veracyte $541.74M 8.41 $66.35M $1.09 52.37 Personalis $64.52M 22.11 -$81.27M -$1.02 N/A

Is VCYT or PSNL more profitable?

Veracyte has a net margin of 16.25% compared to Personalis' net margin of -148.11%. Veracyte's return on equity of 9.07% beat Personalis' return on equity. Company Net Margins Return on Equity Return on Assets Veracyte 16.25% 9.07% 8.38% Personalis -148.11% -43.52% -32.92%

Does the media prefer VCYT or PSNL?

In the previous week, Veracyte had 3 more articles in the media than Personalis. MarketBeat recorded 6 mentions for Veracyte and 3 mentions for Personalis. Veracyte's average media sentiment score of 0.62 beat Personalis' score of 0.29 indicating that Veracyte is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Veracyte 2 Very Positive mention(s) 2 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Personalis 1 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Personalis (PSNL) Competitors

$13.62 0.00 (0.00%)

Closing price 07/2/2026 04:00 PM Eastern

Extended Trading

$13.65 +0.03 (+0.22%)

As of 07/2/2026 07:25 PM Eastern

Compare

PSNL vs. BLLN, CAI, SHC, CELC, and VCYT

Should you buy Personalis stock or one of its competitors? MarketBeat compares Personalis with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Personalis include Billiontoone (BLLN), Caris Life Sciences (CAI), Sotera Health (SHC), Celcuity (CELC), and Veracyte (VCYT). These companies are all part of the "healthcare" industry.

How does Personalis compare to Billiontoone?

Billiontoone (NASDAQ:BLLN) and Personalis (NASDAQ:PSNL) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, media sentiment, risk, profitability, analyst recommendations, valuation, earnings and dividends.

Billiontoone presently has a consensus target price of $126.00, indicating a potential upside of 4.69%. Personalis has a consensus target price of $11.00, indicating a potential downside of 19.24%. Given Billiontoone's higher probable upside, research analysts plainly believe Billiontoone is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Billiontoone	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.50
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

In the previous week, Billiontoone had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for Billiontoone and 3 mentions for Personalis. Personalis' average media sentiment score of 0.29 beat Billiontoone's score of 0.04 indicating that Personalis is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Billiontoone	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Neutral
Personalis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Billiontoone has a net margin of 0.00% compared to Personalis' net margin of -148.11%. Billiontoone's return on equity of 0.00% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Billiontoone	N/A	N/A	N/A
Personalis	-148.11%	-43.52%	-32.92%

Billiontoone has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Billiontoone, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Billiontoone	$354.54M	15.61	$7.45M	$0.55	218.82
Personalis	$64.52M	22.11	-$81.27M	-$1.02	N/A

Summary

Billiontoone beats Personalis on 10 of the 15 factors compared between the two stocks.

How does Personalis compare to Caris Life Sciences?

Personalis (NASDAQ:PSNL) and Caris Life Sciences (NASDAQ:CAI) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their media sentiment, institutional ownership, valuation, earnings, risk, dividends, profitability and analyst recommendations.

Caris Life Sciences has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Caris Life Sciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Personalis	$64.52M	22.11	-$81.27M	-$1.02	N/A
Caris Life Sciences	$348.89M	14.83	-$68.09M	-$7.61	N/A

Personalis presently has a consensus target price of $11.00, indicating a potential downside of 19.24%. Caris Life Sciences has a consensus target price of $27.56, indicating a potential upside of 50.58%. Given Caris Life Sciences' higher possible upside, analysts clearly believe Caris Life Sciences is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57
Caris Life Sciences	1 Sell rating(s)	4 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.45

61.9% of Personalis shares are owned by institutional investors. 4.2% of Personalis shares are owned by company insiders. Comparatively, 50.0% of Caris Life Sciences shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

In the previous week, Caris Life Sciences had 1 more articles in the media than Personalis. MarketBeat recorded 4 mentions for Caris Life Sciences and 3 mentions for Personalis. Caris Life Sciences' average media sentiment score of 0.50 beat Personalis' score of 0.29 indicating that Caris Life Sciences is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Personalis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Caris Life Sciences	1 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Caris Life Sciences has a net margin of 3.75% compared to Personalis' net margin of -148.11%. Caris Life Sciences' return on equity of 98.28% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Personalis	-148.11%	-43.52%	-32.92%
Caris Life Sciences	3.75%	98.28%	48.87%

Summary

Caris Life Sciences beats Personalis on 11 of the 15 factors compared between the two stocks.

How does Personalis compare to Sotera Health?

Sotera Health (NASDAQ:SHC) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, risk, dividends, valuation, media sentiment, earnings, analyst recommendations and profitability.

Sotera Health has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Sotera Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Sotera Health	$1.16B	4.39	$77.94M	$0.41	43.73
Personalis	$64.52M	22.11	-$81.27M	-$1.02	N/A

In the previous week, Personalis had 2 more articles in the media than Sotera Health. MarketBeat recorded 3 mentions for Personalis and 1 mentions for Sotera Health. Sotera Health's average media sentiment score of 0.95 beat Personalis' score of 0.29 indicating that Sotera Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Sotera Health	0 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

91.0% of Sotera Health shares are held by institutional investors. Comparatively, 61.9% of Personalis shares are held by institutional investors. 15.4% of Sotera Health shares are held by company insiders. Comparatively, 4.2% of Personalis shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Sotera Health has a net margin of 9.91% compared to Personalis' net margin of -148.11%. Sotera Health's return on equity of 39.73% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Sotera Health	9.91%	39.73%	7.05%
Personalis	-148.11%	-43.52%	-32.92%

Sotera Health presently has a consensus target price of $20.25, suggesting a potential upside of 12.94%. Personalis has a consensus target price of $11.00, suggesting a potential downside of 19.24%. Given Sotera Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Sotera Health is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Sotera Health	0 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.73
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Sotera Health has a beta of 1.76, suggesting that its stock price is 76% more volatile than the broader market. Comparatively, Personalis has a beta of 2.24, suggesting that its stock price is 124% more volatile than the broader market.

Summary

Sotera Health beats Personalis on 13 of the 16 factors compared between the two stocks.

How does Personalis compare to Celcuity?

Celcuity (NASDAQ:CELC) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, analyst recommendations, dividends, valuation, risk, profitability, institutional ownership and media sentiment.

In the previous week, Personalis had 3 more articles in the media than Celcuity. MarketBeat recorded 3 mentions for Personalis and 0 mentions for Celcuity. Personalis' average media sentiment score of 0.29 beat Celcuity's score of 0.00 indicating that Personalis is being referred to more favorably in the news media.

Company	Overall Sentiment
Celcuity	Neutral
Personalis	Neutral

Celcuity has a beta of 0.16, meaning that its stock price is 84% less volatile than the broader market. Comparatively, Personalis has a beta of 2.24, meaning that its stock price is 124% more volatile than the broader market.

Celcuity currently has a consensus target price of $152.09, indicating a potential upside of 40.89%. Personalis has a consensus target price of $11.00, indicating a potential downside of 19.24%. Given Celcuity's stronger consensus rating and higher probable upside, equities analysts plainly believe Celcuity is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Celcuity	1 Sell rating(s)	0 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.83
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Personalis has higher revenue and earnings than Celcuity. Celcuity is trading at a lower price-to-earnings ratio than Personalis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Celcuity	N/A	N/A	-$177.04M	-$3.90	N/A
Personalis	$64.52M	22.11	-$81.27M	-$1.02	N/A

63.3% of Celcuity shares are owned by institutional investors. Comparatively, 61.9% of Personalis shares are owned by institutional investors. 13.3% of Celcuity shares are owned by insiders. Comparatively, 4.2% of Personalis shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Celcuity has a net margin of 0.00% compared to Personalis' net margin of -148.11%. Personalis' return on equity of -43.52% beat Celcuity's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Celcuity	N/A	-244.61%	-50.22%
Personalis	-148.11%	-43.52%	-32.92%

Summary

Personalis beats Celcuity on 9 of the 15 factors compared between the two stocks.

How does Personalis compare to Veracyte?

Veracyte (NASDAQ:VCYT) and Personalis (NASDAQ:PSNL) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, risk, media sentiment, institutional ownership, earnings and profitability.

Veracyte has a beta of 1.93, indicating that its stock price is 93% more volatile than the broader market. Comparatively, Personalis has a beta of 2.24, indicating that its stock price is 124% more volatile than the broader market.

In the previous week, Veracyte had 3 more articles in the media than Personalis. MarketBeat recorded 6 mentions for Veracyte and 3 mentions for Personalis. Veracyte's average media sentiment score of 0.62 beat Personalis' score of 0.29 indicating that Veracyte is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Veracyte	2 Very Positive mention(s)	2 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Personalis	1 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Veracyte has higher revenue and earnings than Personalis. Personalis is trading at a lower price-to-earnings ratio than Veracyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Veracyte	$541.74M	8.41	$66.35M	$1.09	52.37
Personalis	$64.52M	22.11	-$81.27M	-$1.02	N/A

Veracyte currently has a consensus target price of $50.43, suggesting a potential downside of 11.65%. Personalis has a consensus target price of $11.00, suggesting a potential downside of 19.24%. Given Veracyte's higher possible upside, equities analysts plainly believe Veracyte is more favorable than Personalis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Veracyte	1 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.56
Personalis	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.57

Veracyte has a net margin of 16.25% compared to Personalis' net margin of -148.11%. Veracyte's return on equity of 9.07% beat Personalis' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Veracyte	16.25%	9.07%	8.38%
Personalis	-148.11%	-43.52%	-32.92%

61.9% of Personalis shares are held by institutional investors. 1.4% of Veracyte shares are held by insiders. Comparatively, 4.2% of Personalis shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Summary

Veracyte beats Personalis on 11 of the 17 factors compared between the two stocks.

Get Personalis News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PSNL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PSNL vs. The Competition

Export

Metric	Personalis	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$1.43B	$6.20B	$7.16B	$12.48B
Dividend Yield	N/A	0.64%	2.66%	6.52%
P/E Ratio	-13.35	8.95	28.02	24.70
Price / Sales	22.11	24.94	540.37	99.49
Price / Cash	N/A	8.86	49.26	57.09
Price / Book	4.63	4.40	10.96	6.46
Net Income	-$81.27M	$99.67M	$3.57B	$337.01M
7 Day Performance	4.61%	1.55%	2.12%	1.69%
1 Month Performance	26.70%	8.16%	5.25%	3.81%
1 Year Performance	80.28%	129.25%	33.29%	23.90%

Personalis Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PSNL Personalis	1.7696 of 5 stars	$13.62 flat	$11.00 -19.2%	+80.3%	$1.43B	$64.52M	N/A	400
BLLN Billiontoone	2.5752 of 5 stars	$120.40 +1.9%	$126.00 +4.7%	N/A	$5.44B	$305.11M	218.91	620	News Coverage Insider Trade Gap Up
CAI Caris Life Sciences	4.093 of 5 stars	$18.32 -1.0%	$27.56 +50.4%	N/A	$5.23B	$812.03M	N/A	1,846	Analyst Forecast Gap Up
SHC Sotera Health	3.3121 of 5 stars	$17.52 +0.8%	$20.25 +15.6%	+52.7%	$4.96B	$1.19B	42.73	3,000
CELC Celcuity	2.8211 of 5 stars	$102.52 +2.6%	$152.09 +48.4%	+682.8%	$4.87B	N/A	N/A	40

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PSNL) was last updated on 7/5/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Personalis (PSNL) Competitors

PSNL vs. BLLN, CAI, SHC, CELC, and VCYT

How does Personalis compare to Billiontoone?

Summary

How does Personalis compare to Caris Life Sciences?

Summary

How does Personalis compare to Sotera Health?

Summary

How does Personalis compare to Celcuity?

Summary

How does Personalis compare to Veracyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Personalis (PSNL) Competitors

PSNL vs. BLLN, CAI, SHC, CELC, and VCYT

How does Personalis compare to Billiontoone?

Do analysts recommend BLLN or PSNL?

Does the media refer more to BLLN or PSNL?

Do insiders & institutionals have more ownership in BLLN or PSNL?

Is BLLN or PSNL more profitable?

Which has higher earnings and valuation, BLLN or PSNL?

Summary

How does Personalis compare to Caris Life Sciences?

Which has preferable earnings & valuation, PSNL or CAI?

Do analysts rate PSNL or CAI?

Do institutionals and insiders have more ownership in PSNL or CAI?

Does the media favor PSNL or CAI?

Is PSNL or CAI more profitable?

Summary

How does Personalis compare to Sotera Health?

Which has higher valuation and earnings, SHC or PSNL?

Does the media prefer SHC or PSNL?

Do institutionals and insiders have more ownership in SHC or PSNL?

Is SHC or PSNL more profitable?

Do analysts prefer SHC or PSNL?

Which has more risk & volatility, SHC or PSNL?

Summary

How does Personalis compare to Celcuity?

Does the media favor CELC or PSNL?

Which has more risk & volatility, CELC or PSNL?

Do analysts prefer CELC or PSNL?

Which has preferable valuation & earnings, CELC or PSNL?

Do institutionals and insiders hold more shares of CELC or PSNL?

Is CELC or PSNL more profitable?

Summary

How does Personalis compare to Veracyte?

Which has more volatility & risk, VCYT or PSNL?

Does the media prefer VCYT or PSNL?

Which has higher valuation and earnings, VCYT or PSNL?

Do analysts prefer VCYT or PSNL?

Is VCYT or PSNL more profitable?

Do insiders & institutionals hold more shares of VCYT or PSNL?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PSNL vs. The Competition

Personalis Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools